Alnylam Pharmaceuticals | ALNY - Assets



Alnylam Pharmaceuticals reported $4.57B in Assets for its fiscal quarter ending in June of 2025.


Assets Change Date
Acadia Pharmaceuticals USD 1.23B 93.19M Jun/2025
Agios Pharmaceuticals USD 1.47B 84.28M Jun/2025
Alnylam Pharmaceuticals USD 4.57B 352.21M Jun/2025
Amgen USD 87.9B 1.47B Jun/2025
Arrowhead Research USD 1.38B 192.89M Jun/2025
BioMarin Pharmaceutical USD 7.46B 309.33M Jun/2025
Incyte USD 5.82B 71.99M Jun/2025
Ionis Pharmaceuticals USD 2.99B 172.18M Jun/2025
Moderna USD 12.01B 694M Jun/2025
Neurocrine Biosciences USD 3.89B 202.1M Jun/2025
Novartis USD 104.4B 2.15B Jun/2025
PTC Therapeutics USD 2.63B 21.23M Jun/2025
Regeneron Pharmaceuticals USD 38.22B 674M Jun/2025
Sanofi 124.96B 7.84B Jun/2025
Sarepta Therapeutics USD 3.68B 214.43M Jun/2025
Takeda JPY 14T 243.81B Jun/2025
Tectonic Therapeutic USD 295.31M 142.4M Jun/2025
Ultragenyx Pharmaceutical USD 1.31B 5.66M Jun/2025
Vertex Pharmaceuticals USD 24.04B 1.16B Jun/2025
Xencor USD 879.42M 25.26M Jun/2025